Figure 3.

Overall survival (OS) after treatment with azacitidine ± DLI in 66 patients with MDS and sAML with 20–29% BM blasts (formerly RAEB-T) based on a scoring system including relapse type and pretransplant strategy. One point was assigned for molecular relapse, while two points were given for diagnosis of hematologic relapse. Upfront transplantation was assigned zero points, while for application of HMA or intensive CTX prior transplant one point was given. As such, the model enables a stratification of patients into three distinct risk categories (favorable = 1 point, intermediate = 2 points, unfavorable = 3 points)